Impact of changing PICCline dressings on infection rates in leukemia patients
Study of the Impact of Frequency of Changing PICCline Dressings in Patients With Acute Leukemia
This study is testing if changing the dressings on PICC lines more often can help reduce infection rates in leukemia patients receiving chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Montpellier) |
| Trial ID | NCT05793801 on ClinicalTrials.gov |
What this trial studies
This study investigates the effect of increasing the frequency of dressing changes for Peripherally Inserted Central Catheters (PICC) in patients with acute leukemia undergoing intensive chemotherapy. The hypothesis is that more frequent dressing changes will lead to a reduction in catheter-related infections, which are a significant risk for these patients. The study will involve patients who have recently had a PICCline placed and will monitor infection rates associated with different dressing change intervals. The research aims to provide evidence-based recommendations for best practices in managing PICClines in hematology.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with acute myeloblastic leukemia who are about to start intensive induction chemotherapy.
Not a fit: Patients who have had a PICCline placed during a previous hospitalization or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of infections in leukemia patients receiving chemotherapy, improving their overall treatment outcomes.
How similar studies have performed: While there is limited direct evidence comparing different dressing change frequencies for PICClines, the study addresses a gap in existing literature and builds on previous observational findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with a diagnosis of acute myeloblastic leukemia. * Patient going on intensive induction chemotherapy (causing a "high risk" situation of severe infection defined as profound neutropenia ( Polymorphonuclear neutrophil count \<500/mm3) and lasting (\>7 days). * Patients who have had a PICCline placed within the last 24 hours or who require a PICCline placement as part of their hospitalization under optimal hygiene and asepsis conditions. * Patient housed in a protected environment (flow chamber or Plasmair®). * Patient who has given free and informed consent. * Patient affiliated or beneficiary of a health insurance plan. * Adult patient (≥18 years old). Exclusion Criteria: * Patient with PICCline placed during a previous hospitalization. * Patient in an exclusion period determined by another study. * Patient under court protection, guardianship or curatorship. * Patient unable to give consent. * Patient for whom it is impossible to give informed information.
Where this trial is running
Montpellier
- CHU de Montpellier Hôpital St-Eloi — Montpellier, France (Recruiting)
Study contacts
- Principal investigator: Julie LASSALLE, Mme. — Centre Hospitalier Universitaire de Nīmes
- Study coordinator: Éric JOURDAN, Dr.
- Email: Eric.jourdan@chu-nimes.fr
- Phone: +334.66.68.32.34
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.